Amiral Gestion Grows Stock Position in Edwards Lifesciences Corporation $EW

Amiral Gestion lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 156.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 282,795 shares of the medical research company’s stock after acquiring an additional 172,481 shares during the quarter. Edwards Lifesciences makes up 8.0% of Amiral Gestion’s holdings, making the stock its 4th biggest holding. Amiral Gestion’s holdings in Edwards Lifesciences were worth $21,993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Edwards Lifesciences by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock valued at $5,474,515,000 after purchasing an additional 798,801 shares during the period. Geode Capital Management LLC boosted its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after purchasing an additional 45,555 shares during the last quarter. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after buying an additional 1,584,958 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares during the period. Finally, Norges Bank bought a new position in Edwards Lifesciences during the second quarter worth $580,640,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on EW shares. Wells Fargo & Company set a $100.00 price target on shares of Edwards Lifesciences in a research report on Thursday. Truist Financial set a $92.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, December 5th. Citigroup reaffirmed a “buy” rating and set a $101.00 target price (up previously from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. National Bankshares set a $92.00 target price on Edwards Lifesciences in a report on Friday, October 31st. Finally, Evercore ISI increased their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $93.95.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,465 shares of company stock valued at $3,804,610 in the last 90 days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

EW opened at $84.73 on Friday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company has a market capitalization of $49.17 billion, a price-to-earnings ratio of 36.52, a P/E/G ratio of 3.81 and a beta of 0.97. The firm’s fifty day moving average price is $82.30 and its two-hundred day moving average price is $79.22.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period last year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.